David Maggs
Vorstandsvorsitzender bei Abvance Therapeutics, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Steve Daly | M | - |
Abvance Therapeutics, Inc.
 Abvance Therapeutics, Inc. BiotechnologyHealth Technology Abvance Therapeutics, Inc. is a pharmaceutical company that aims to improve diabetes control and reduce the risk of hypoglycemia. The company is based in Reno, NV. The company's Abv100 platform is designed to replace rapid acting insulin and can be used by any patient type, including those with type 1 and type 2 diabetes who use injections or pumps. The platform protects against hypoglycemia, allowing for safer use of insulin and better control of diabetes, which can lead to improved long-term health outcomes. The company was founded in 2016 by Alan Cherrington, David Maggs, and Soumitra Ghosh. David Maggs has been the CEO since 2016. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Michael D. Dale | M | 64 | 2 Jahre | |
| Robert Crane | M | 65 | 11 Jahre | |
| Stuart Randle | M | 64 | 11 Jahre | |
| Daniel Moore | M | 63 | 6 Jahre | |
| Andrew Levine | M | - | 11 Jahre | |
| Alan Cherrington | M | - |
Abvance Therapeutics, Inc.
Abvance Therapeutics, Inc. BiotechnologyHealth Technology Abvance Therapeutics, Inc. is a pharmaceutical company that aims to improve diabetes control and reduce the risk of hypoglycemia. The company is based in Reno, NV. The company's Abv100 platform is designed to replace rapid acting insulin and can be used by any patient type, including those with type 1 and type 2 diabetes who use injections or pumps. The platform protects against hypoglycemia, allowing for safer use of insulin and better control of diabetes, which can lead to improved long-term health outcomes. The company was founded in 2016 by Alan Cherrington, David Maggs, and Soumitra Ghosh. David Maggs has been the CEO since 2016. | - |
| Jennifer D. Haldeman | F | 59 |
Parke, Davis & Co. LLC
| 9 Jahre |
| Mark C. Twyman | M | 63 | 3 Jahre | |
| Erin Moore | F | 49 | 3 Jahre | |
| Soumitra Ghosh | M | - |
Abvance Therapeutics, Inc.
Abvance Therapeutics, Inc. BiotechnologyHealth Technology Abvance Therapeutics, Inc. is a pharmaceutical company that aims to improve diabetes control and reduce the risk of hypoglycemia. The company is based in Reno, NV. The company's Abv100 platform is designed to replace rapid acting insulin and can be used by any patient type, including those with type 1 and type 2 diabetes who use injections or pumps. The platform protects against hypoglycemia, allowing for safer use of insulin and better control of diabetes, which can lead to improved long-term health outcomes. The company was founded in 2016 by Alan Cherrington, David Maggs, and Soumitra Ghosh. David Maggs has been the CEO since 2016. | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 11 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- David Maggs
- Persönliches Netzwerk
